Purpose: To investigate molecular alterations in choroid plexus tumors (CPTs) using a genome-wide high-throughput approach, in order to identify diagnostic and prognostic signatures that will refine tumor stratification and guide therapeutic options.
TRANSLATIONAL RELEVANCE:
This report is the first to dissect the aberrant complexity in copy number, methylation, and gene expression of one of the largest cohort of pediatric choroid plexus tumors (CPTs). Our findings revealed molecular homogeneity among choroid plexus papillomas (CPPs) and atypical choroid plexus papillomas (aCPPs), reflecting the favourable survival of these patients and suggesting these histologically distinct subgroups are a single tumor entity. Choroid plexus carcinomas (CPCs) were significantly different from CPPs and aCPPs. Moreover, CPCs exhibited molecular heterogeneity, and patient outcomes varied widely. We identified novel CPC subgroups with significantly distinct copy number signatures suggesting different mechanisms drive CPC development. We identified novel CPC subgroups with significantly distinct copy number signatures suggesting different mechanisms drive CPC development. We identified that patient overall and event-free survival significantly decreased with an increasing number of mutated copies of p53. By defining the molecular landscape of CPTs, this study has provided a comprehensive molecular background on which to explore mechanisms of tumorigenesis and develop stratified approaches to the clinical management of CPTs. and most of the few survivors exhibit long-term cognitive and developmental deficits. (6) aCPP, a recently described pathological subgroup, exhibits an intermediate degree of mitotic activity and outcome; (7, 8) however, some cases may be difficult to distinguish from CPC by histology alone. (9) Over 50% of CPC tumors carry somatic TP53 mutations, and TP53 mutant CPCs have been associated with increased genetic tumor instability and worse prognosis. (5) Germline TP53 mutations have also been observed in CPC patients as CPC is one of the hallmark cancers of the Li-Fraumeni syndrome (LFS), a familial cancer syndrome in which affected family members harbor a mutant copy of the TP53 tumor suppressor gene.
Cytogenetic studies of central nervous system (CNS) tumors have revealed high chromosomal instability in more than 90% of CPTs analyzed (Supplementary Table S1 ).
Defining the molecular landscape of CPTs and identifying actionable molecular aberrations has been challenging due in part to the limited number of patients and highquality samples available for genome-wide studies. Here, we use an integrative molecular approach to characterize the genomic, transcriptomic and epigenomic landscape of the largest cohort of CPTs to date. The information derived from these analyses creates a molecular foundation on which to develop approaches to improve the clinical management of this devastating disease.
MATERIALS and METHODS

Patients and Sample Preparation
CPT samples and/or clinical data were collected from institutions in Canada, the United States of America, Brazil, Israel, and Germany (see Appendix) in accordance with each institution's Research Ethics Board. Informed consent was obtained from the parents/legal guardians of all patients. We studied 100 unique tumor samples (58 CPC, 30 CPP and 12 aCPP) from 91 pediatric patients (ages 0.03-16.50 years old) for which TP53 sequence data was available (Table S2 ). Pathological review of CPTs was conducted by C.H., D.W.E., and B.T.H. when samples were available. In all other institutions, expert neuropathologists critically examined each case. In fifteen CPC cases, immunohistochemical analysis of hHF5/INI1 was conducted and revealed immunopositivity excluding the diagnosis of atypical teratoid/rhabdoid tumors (ATRT).
Nucleic acids were derived from fresh frozen (n=75), optimal cutting temperature compound (OCT) (n=9), and formalin-fixed paraffin-embedded (FFPE) (n=12) samples.
We received isolated tumor DNA from 4 samples. Twenty-two nucleic acid samples exhibited suboptimal quality and/or quantity, leaving 78 high-quality samples from 73 patients for analysis ( Supplementary Fig. S1 ). Detailed clinical data were obtained for 68 patients. Tumor DNA was extracted using standard phenol-chloroform extraction from 
TP53 Sequencing
Sequencing of the coding region of TP53 (exons 2-11) was performed in the molecular diagnostic laboratory at The Hospital for Sick Children (Toronto) by direct Sanger sequencing of whole genome DNA as previously described. were used for copy number analysis as previously described (5) chromosome aberrations. Allele-specific copy number analysis of tumors (ASCAT) was performed in R as previously described (10) and verified by Nexus software. Tumor ploidy, where hypodiploid <1.90 and hyperdiploid >2.10, heterogeneity, and allelic imbalances were inferred from the output. ASCAT failed to resolve the ploidy of two samples with very low aberrant fraction, so these were excluded from further analysis.
Clustering of gene expression and methylation data was investigated in R (version 3.0.1) by unsupervised hierarchical clustering (uHCL), non-negative matrix factorization (NMF), and PVCLUST algorithms. Differential gene expression analysis was conducted with PGS 6.5 (see Appendix). Gene set enrichment analysis (GSEA) was performed as previously described (11) 
Statistical analysis
Statistical analyses of copy number and gene expression were performed in PGS 6.5, whereas methylation was analyzed in Genome Studio. Patient survival was calculated in StataSE (version 12), while other statistical analyses were conducted in R (version 3.0.1) (see Appendix). Survival estimates for tumor subgroups, and for CPCs by TP53 and ploidy status were generated using the Kaplan-Meier method and curves were compared (Fig. 2) . The frequency of chromosome-wide losses in CPCs was significantly greater than in CPPs and aCPPs (Two-tailed t-test p<1.00 x10 -4 ). Allele-specific copy number analysis allowed us to investigate the allelic ratios in our samples. This technique revealed a striking pattern of copy number-neutral loss of heterozygosity. This phenomenon is commonly observed in cancer cells and may also be referred to as acquired uniparental disomy (aUPD), wherein a chromosome pair is homozygous, thus having two copies of the same allele (13 Analyzing CPPs and aCPPs independently from CPCs revealed a striking molecular similarity between the papilloma subgroups (Fig. 4) . Unsupervised clustering analysis demonstrated that CPPs and aCPP did not segregate according to differences in gene expression or methylation (Fig. 4 A&B) . Supervised analysis using the Wilcoxon ranksum (WRS) test between CPPs and aCPPs revealed no significant differences in gene expression or methylation (Fig. 4 C&D) . Additionally, signatures of chromosomal instability characterized by recurrent chromosome-wide gains and very few losses were observed in both CPPs and aCPPs; no significant differences in the frequency of chromosome-wide gains and losses were observed (Two-tailed t-test p=0.32 and p=0.49, respectively) (Fig. 4E ). There were no differences in age at diagnosis (Mann-Whitney test p=0.45) or ratio of males to females (Fisher's Exact test p=0.31) between CPPs and aCPPs. Moreover, survival outcomes for CPP and aCPP patients were not significantly different (Log-Rank test, OS p=0.51, EFS p=0.30).
Ploidy Analysis Reveals Novel CPC Subgroups With Unique Molecular Alterations
Ploidy analysis revealed the presence of aneuploidy in 87% of tumors ( Supplementary   Fig. S3 ). CPPs and aCPPs exhibited ploidy greater than 2 (hyperdiploidy); however, 
chromosomes 6, 9, and 22 observed in 90% of tumors (Fig. 3A) . Hyperdiploid CPCs exhibited a high frequency of chromosome-wide gains and almost no losses (average 12.22 and 0.22 chromosomes, respectively). Chromosomes 12, 7 and 1 were gained in more than 80% of hyperdiploid CPCs (Fig. 3A) . (Fig. 3A) . Moreover, significant enrichment in aUPD was observed in TP53 mutant hyperdiploid CPCs compared to hyperdiploid CPCs with wild-type TP53 (Fisher's Exact test p<0.0001).
aUPD was most frequently observed in chromosome 17, affecting 30% (10/33) of CPCs.
We conducted GSEA to identify biological pathways and processes that are differentially expressed between hypodiploid and hyperdiploid CPCs. GSEA revealed enrichment in RNA processing, DNA replication and repair, and chromosome segregation in hyperdiploid CPCs. Hypodiploid CPCs exhibited enrichment in cellular metabolism, signaling and cell migration pathways, as well as leukocyte activation and proliferation (5% FDR, p<0.05) (Supplementary Fig. S4 ). The patterns of enrichment observed suggest hyperdiploids are more proliferative than hypodiploid CPCs, and that the latter tumors are undergoing a significant immune response. A greater understanding of these distinct enrichment patterns will elucidate the mechanisms underlying the progression of these molecularly distinct CPC subgroups (Supplementary Fig. S4 ). There were no significant differences in DNA methylation between subgroups, although this may be due to the low number of samples in the comparison groups (hypodiploid n=4, hyperdiploid n=9).
Research. Table S3 ). No significant enrichment for LFS patients was observed in either hypo-or hyperdiploid subgroups.
Unsupervised clustering using gene expression and methylation data segregated CPCs into two significantly distinct clusters (p=0.05) (Fig. 5A & B) . Although CPCs did not segregate according to ploidy status, we observed two clusters, which were significantly distinct according to TP53 status using DNA methylation data (Fisher's Exact test, p=0.007), but did not reach significance using gene expression data (Fisher's Exact test, p=0.089). LFS-CPCs did not segregate from the spontaneous CPCs, suggesting no unique aberrations were present in tumors arising from patients with an inherited TP53
mutation. An in-depth analysis of the type of TP53 mutations revealed that a few samples, which appeared to be miscategorized by unsupervised clustering, had an uncharacterized intronic alteration (c.28-28G>A/wt) and mutations outside the DNAbinding domain (ie. c.290T>A in the SH3-like/Proline-rich domain), which may account for differences in the transcriptomic and epigenomic signature of these samples (Fig. 5) . Examining clinical variables among CPCs revealed no differences in the age of diagnosis (Mann-Whitney t-test p=0.80, and p=0.59) or the ratio of males to females (Fisher's Exact test p=1.0, and p=1.0) according to ploidy nor p53 status, respectively (Table S2) . ( Supplementary Fig. S5A & B) . TP53 status had a significant effect on the OS of our CPC cohort (Log-rank test p=3.8x10 -3 ), however EFS was not significantly different between TP53 mutant and wildtype CPCs (p=0.07). (Fig. 5C & D (Fig. 6 ).
DISCUSSION
Our study is the first and largest comprehensive investigation of the molecular alterations found in CPTs, demonstrating that the molecular profile of CPCs is significantly distinct from that of CPPs and aCPPs, and that the papillomas are not significantly distinct from each other. In addition, using an innovative allele-specific approach in combination with 
Extensive chromosomal alterations were recurrent in CPCs. An allele-specific copy number approach allowed us to identify aneuploidy in 91% of CPCs, and distinguish between hypodiploid CPCs, exhibiting numerous chromosomal losses, and hyperdiploid CPCs, exhibiting numerous chromosomal gains and concurrent aUPD. Our findings uncovered that chromosomal instability is a common mechanism involved in CPC development; however, further examination of the molecular differences driving hypoand hyperdiploid development will identify distinct mechanisms responsible for tumor progression. Ploidy was not significantly associated with age at diagnosis, or patient survival; nonetheless, we identified that hyperdiploid CPCs were significantly enriched in chromosomes exhibiting aUPD. A recent study reported similar subgroupings in CPCs, where a higher frequency of chromosomal losses were observed in younger children and chromosomal gains in older children, and loss of 12q was associated with shorter survival (18) . In our cohort we found no significant correlations between patient age and CPC subgroups or TP53 status. Moreover, survival differences were identified only when TP53 copy number and mutation status were examined concomitantly.
Arising from somatic recombination errors during mitosis, aUPD is an important mechanism leading to loss of heterozygosity with an unaffected copy number, and is therefore associated with the enrichment of chromosomes or regions harboring preexisting mutations, specific promoter methylation patterns, and focal deletion of genes (13) . In our study, we observed aUPD affect entire chromosomes in all tumor subgroups, however aUPD was most frequent in CPCs harboring TP53 mutations. We identified chromosome 17 to be the most frequent site affected by aUPD, and that 90% of CPCs exhibiting aUPD of chromosome 17 harbored a mutation in TP53, increasing the number of mutant p53 copies to 2 in these tumors. Our findings suggest aUPD is a mechanism by which CPCs accumulate deleterious aberrations, such as TP53 mutations, while retaining the normal function of other genes due to an unaffected chromosome copy number.
Focusing on the known association between p53 mutations and CPCs, we identified that the number of mutated copies of p53 was significantly associated with patient survival.
Our findings support the concept that in addition to the loss of tumor-suppressive activity of p53, mutant TP53 also acquires oncogenic activities that promote CPC development.
The gain of function (GOF) properties of mutant p53 include cellular invasion, proliferation, genomic instability, and polyploidy, among others (Reviewed in (19) ).
Because of increased GOF activity, in addition to a complete loss of the tumor suppressor functions of p53, an elevated number of mutant p53 copies could result in an aggressive phenotype associated with decreased survival as we observed in our high risk CPC patient cohort. Since we did not assess the mutation status of other cancer genes in chromosome 17, we cannot infer that the number of mutant copies of p53 is the only aberration on this locus driving CPC development and tumor aggressiveness in the high risk CPC patient cohort. However, the significant dose-dependent correlation observed with overall and event-free survival in CPC patients indicates a role for p53 GOF activity in CPC aggressiveness. Recurrent lesions, such as the chromosome-wide gains of chromosome 1, which was not only recurrently gained but also the least frequently lost in CPCs, chromosome 12, and chromosome-wide loss of chromosome 3, may also be contributing to CPC's unique genotype and would need to be further investigated in order to identify unique targets for effective therapies.
Our study demonstrates that investigating the molecular characteristics of CPTs is crucial to further refine the molecular stratification of patients in order to improve patient care.
We suggest that the prognostic significance of TP53 mutation and copy number status in CPCs be validated prospectively in future cooperative clinical trials. Validation of these data in future prospective studies will inform risk stratification of CPC patients, and set the framework for future treatment intensification for high-risk patients. No segregation was observed between CPPs and aCPPs. NMF was conducted using 5000 probesets with the largest median absolute deviation (MAD). This clustering algorithm identified the most significant measures of similarity (cophenetic coefficient) when the data was at k=2 (2 clusters). In the matrix, red represents the highest measure of similarity (1), while blue/purple represents the lowest measure of similarity (0). Any other colors within the matrix represent a spectrum of changing measures of similarity, from red to blue/purple. Colors: TP53 mutation status: Black: TP53 mutant, White: TP53 wildtype. methylation Beta values demonstrate no segregation between CPPs (yellow) and aCPPs (light blue). Volcano plot comparing the number of significant differentially expressed genes (C) and significantly methylated regions (D) reveals no significant gene expression or methylation differences between the two subgroups (after FDR adjustment). Signatures of chromosomal instability (E), as measured by the number of chromosome-wide gains and losses in CPPs and aCPPs, were similar between the two subgroups and characterized by extensive chromosomal gains and very few losses. Black squares represent chromosome-wide aberrations, while white squares represent unchanged chromosome copy number. Gender was also depicted (pink: female, purple: male). 
